Article Text

AB0588 Experience of tocilizumab using for resistant adult-onset still’s disease
  1. Y. Muraviev1,
  2. M. Podryadnova2,
  3. E. Nasonov2
  1. 1Laboratory for Studying the Safety of Antirheumatic Therapy
  2. 2Federal State Budgetary Instuitution “Research Institute of Rheumatology” of Rus. Acad. Med. Sci, Moscow, Russian Federation


Background Adult onset Still’s disease (AOSD) is the systemic inflammatory disease. Blockade of interleukin receptors (IL-6) neutralizes the induction of acute phase reaction, which could be used in the therapy of the resistant AOSD.

Objectives To assess Tocilizumab efficacy in the resistant AOSD.

Methods The study included 6 women and 1 man with AOSD adopted to clinical department of the Institute, corresponding to Yamaguchi et al criteria, average age 34.2±10.7 y/o, average disease duration – 4.7±4.0 years who regularly had NSAIDs, prednisolone 17.5-50 mg/day, methotrexate 10-15 mg/week.

Results All included into the study pts, in spite of drug treatment, demonstrated fever >39°C, typical rush, arthritides, leukocytosis >10×109/l, in 5 –throat pain, in 4 – hepatic disturbances and lymphadenopathy, which was the basis for Tocilizumab prescription in doses 8mg/kg of body weight every 4 weeks. After the first Tocilizumab infusion: temperature was normal in 6 pts in 24 hrs and in 1 in 48 hrs; arthritis symptoms disappeared in 2 pts and significantly subsided in 5; CRP level subsided in all pts. Therapy is continued in 6 pts (2-11 infusions). AOSD remission was noticed in 1 patient, improvement in 56.

Conclusions Tocilizumab can be the drug of choice in the resistant AOSD.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.